Aclaris Therapeutics
ACRS
104 hedge funds and large institutions have $694M invested in Aclaris Therapeutics in 2017 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 56 increasing their positions, 23 reducing their positions, and 24 closing their positions.
143% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 23
5.1% more ownership
Funds ownership: 90.71% → 95.81% (+5.1%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
2% less capital invested
Capital invested by funds: $707M → $694M (-$12.8M)
5% less funds holding
Funds holding: 110 → 104 (-6)
25% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$27.4M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$19M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
+$15.1M |
| 4 |
BlackRock
New York
|
+$11.4M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$10.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$37.6M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$13.4M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$13.3M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$6.39M |
| 5 |
Fidelity International
Hamilton,
Bermuda
|
-$5.83M |
ACRS Hedge Fund Activity: Q2 2017 in Review
104 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q2 2017, worth a combined $694M — down 1.8% from $707M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of ACRS and 18 opened new positions — a net loss of 6 holders — while 23 trimmed existing stakes and 56 added.
The largest buyer was Eagle Asset Management, adding an estimated $27.4M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $37.6M sold.
- 104 institutional investors held Aclaris Therapeutics (ACRS) as of Q2 2017, down from 110 in Q1 2017.
- Funds reported $694M of Aclaris Therapeutics stock for Q2 2017, down 1.8% quarter-over-quarter.
- 18 funds opened new Aclaris Therapeutics positions in Q2 2017 and 24 closed out, a net change of -6 holders.
- The largest Aclaris Therapeutics buyer in Q2 2017 was Eagle Asset Management, an estimated $27.4M added.
- The largest Aclaris Therapeutics seller in Q2 2017 was Perceptive Advisors, an estimated $37.6M sold.
Based on aggregated 13F filings for Q2 2017.